Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells

Latency-reversing agents and cellular activation affect antigen processing in primary CD4 T cells

Bibliographic Details
Main Authors:	J. Boucau, J. Madouasse, D. Wambua, M.J. Berberich, S. Le Gall
Format:	Article
Language:	English
Published:	Elsevier 2015-12-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020313169

Similar Items

Drug-induced modulation of cellular activation during latency reversal changes antigen processing and peptide presentation in primary CD4 T cells
by: J. Boucau, et al.
Published: (2017-12-01)

Latency reversal agents modulate HIV antigen processing and presentation to CD8 T cells.
by: Julie Boucau, et al.
Published: (2020-03-01)

Effect of HIV infection on the expression and the activity of the proteasome in primary CD4 T cells
by: Boucau J, et al.
Published: (2012-09-01)

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
by: Judith Grau-Expósito, et al.
Published: (2019-08-01)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016-07-01)

The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells
by: G. Sampey, et al.
Published: (2019-07-01)

Approaches to discover latency-reversing agents
Published: (2015-12-01)

Memory CD4+ T cell subsets show differential responses to HIV latency-reversing agents
by: D.A. Kulpa, et al.
Published: (2015-12-01)

Impact of latency‐reversing agents on human macrophage physiology
by: Laurent Hany, et al.
Published: (2023-01-01)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
by: Amina Ait-Ammar, et al.
Published: (2020-01-01)

The Effect of Latency Reversal Agents on Primary CD8+ T Cells: Implications for Shock and Kill Strategies for Human Immunodeficiency Virus Eradication
by: Victoria E. Walker-Sperling, et al.
Published: (2016-06-01)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019-12-01)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019-12-01)

Latency Reversing Agents: Kick and Kill of HTLV-1?
by: Annika P. Schnell, et al.
Published: (2021-05-01)

Reanalysis of Gene Expression Profiles of CD4+ T Cells Treated with HIV-1 Latency Reversal Agents
by: Antonio Victor Campos Coelho, et al.
Published: (2020-09-01)

Diverse Impacts of HIV Latency-Reversing Agents on CD8+ T-Cell Function: Implications for HIV Cure
by: Genevieve Tyndale Clutton, et al.
Published: (2018-06-01)

OP 2.7 – 00057 The latency reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific CD8+ T-cells
by: D.C. Copertino, et al.
Published: (2022-12-01)

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4⁺ T-Cells to Recognition by Cytotoxic T-Lymphocytes
by: O’Connor, Rachel, et al.
Published: (2017)

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.
by: R Brad Jones, et al.
Published: (2016-04-01)

Identification of a promising new class of latency reversing agents
by: A. Gramatica, et al.
Published: (2017-12-01)

OP 2.8 – 00193 Enhancing PKC Modulator HIV Latency Reversing Agents
by: M. Marsden, et al.
Published: (2022-12-01)

Tissue-specific effects of latency-reversing agents on HIV transcriptional blocks in gut and blood
by: S. Telwatte, et al.
Published: (2019-07-01)

Lymphoid tissue and blood CD4 T cells respond differently to latency-reversing agents: are we testing the right cells?
by: A. Gramatica, et al.
Published: (2015-12-01)

HIV latency reversing agents act through Tat post translational modifications
by: Georges Khoury, et al.
Published: (2018-05-01)

Latency-Reversing Agents Induce Differential Responses in Distinct Memory CD4 T Cell Subsets in Individuals on Antiretroviral Therapy
by: Marion Pardons, et al.
Published: (2019-11-01)

Histone deacetylase inhibitors induce transcription of unspliced but not multiply spliced HIV-1 RNA from proviral genomes during latency reversal, affecting antigen presentation and detection by CD8+ T cells
by: T. Mota, et al.
Published: (2019-12-01)

Optimal Control of an HIV Model with Gene Therapy and Latency Reversing Agents
by: Zachary Abernathy, et al.
Published: (2021-11-01)

Insights into mechanisms of HIV reactivation from latency using RNA-Seq gene expression profiling in CD4+ T cells and their maturation subsets following treatment with latency reversing agents.
by: N. Beliakova-Bethell, et al.
Published: (2017-12-01)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015-12-01)

Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency
by: Daniela A. Covino, et al.
Published: (2021-06-01)

PP 5.4 – 00184 Optimization of Smac Mimetics as HIV-1 Latency Reversing Agents
by: L. Pache, et al.
Published: (2022-12-01)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017-12-01)

Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019-12-01)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015-12-01)

Novel use of alprazolam as a potential HIV-1 latency reversing agent
by: W. Elbezanti, et al.
Published: (2017-12-01)

The latency-reversing agent HODHBt synergizes with IL-15 to enhance cytotoxic function of HIV-specific T cells
by: Dennis C. Copertino Jr., et al.
Published: (2023-09-01)

Evaluation of IAP/SMAC mimetics as latency reversal agents in primary cells and cytokine induction in in vivo models predictive of cytokine release
by: B. Howell, et al.
Published: (2019-12-01)

Discovering the Mechanisms of Oleodaphnone as a Potential HIV Latency-Reversing Agent by Transcriptome Profiling
by: Shifei Li, et al.
Published: (2023-04-01)

Molecular Modeling and Synthesis of New HIV Latency-Reversing Agents Targeting the Lymphatic System
by: Beatriz Meduqui Rodrigues, et al.
Published: (2022-11-01)

Epigenetic Regulation of HIV-1 Sense and Antisense Transcription in Response to Latency-Reversing Agents
by: Rui Li, et al.
Published: (2023-01-01)